Supplementary Material. Outcomes of Down-Titration in Patients with Severe Scalp Alopecia Areata Initially Treated with Baricitinib 4-mg: Week 152 data from BRAVE-AA2

eTable 1. Percentage of patients with a SALT score ≤20 at each post Week 52 visit
eTable 2. Percentage of patients with loss of treatment benefit through Week 152.
eTable 3. Baseline demographics and disease measures for patients down-titrated at Week 52 and experienced a loss of treatment benefit vs those who did not experience a loss of treatment benefit.
eTable 4. Summary of safety outcomes
eFigure 1. A) Sustained response (SALT score ≤20 from Weeks 36 to 52) and B) higher depth of response (SALT score ≤5 at randomized down-titration) were associated with a lower incidence of loss of treatment benefit.
eFigure 2. Proportion of patients with a response in A) eyebrow or B) eyelash regrowth from Weeks 52 to 152 for patients down-titrated at Week 52 versus those who remained on their original treatment dose.